Health Catalyst (NASDAQ:HCAT) Price Target Lowered to $1.75 at Citigroup

Health Catalyst (NASDAQ:HCAT) had its price objective lowered by Citigroup from $2.75 to $1.75 in a research report report published on Friday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Health Catalyst in a report on Monday, December 29th. Canaccord Genuity Group decreased their price target on shares of Health Catalyst from $5.00 to $2.00 and set a “buy” rating on the stock in a research note on Friday. Stephens lowered their price target on shares of Health Catalyst from $3.50 to $2.00 and set an “equal weight” rating on the stock in a research report on Friday. Stifel Nicolaus dropped their price objective on shares of Health Catalyst from $3.75 to $2.00 and set a “hold” rating for the company in a research note on Friday. Finally, Cantor Fitzgerald cut their price objective on shares of Health Catalyst from $4.00 to $3.00 and set a “neutral” rating for the company in a report on Friday. Five investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $3.16.

Health Catalyst Stock Performance

Shares of NASDAQ:HCAT opened at $1.32 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.88 and a quick ratio of 1.88. Health Catalyst has a 1 year low of $1.20 and a 1 year high of $5.06. The firm has a market capitalization of $93.36 million, a PE ratio of -0.52 and a beta of 1.76. The business’s 50 day moving average price is $2.05 and its 200-day moving average price is $2.57.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Thursday, March 12th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.02). The firm had revenue of $74.68 million during the quarter, compared to analyst estimates of $73.99 million. Health Catalyst had a negative net margin of 57.20% and a negative return on equity of 3.98%. As a group, equities research analysts expect that Health Catalyst will post -0.33 earnings per share for the current fiscal year.

Institutional Trading of Health Catalyst

Hedge funds and other institutional investors have recently modified their holdings of the business. First Light Asset Management LLC increased its holdings in Health Catalyst by 17.2% in the 2nd quarter. First Light Asset Management LLC now owns 12,230,181 shares of the company’s stock valued at $46,108,000 after purchasing an additional 1,793,374 shares during the last quarter. Millennium Management LLC lifted its stake in Health Catalyst by 2,513.3% during the third quarter. Millennium Management LLC now owns 1,589,536 shares of the company’s stock worth $4,530,000 after purchasing an additional 1,528,710 shares in the last quarter. RA Capital Management L.P. purchased a new position in shares of Health Catalyst during the fourth quarter worth $1,897,000. HighMark Wealth Management LLC boosted its position in shares of Health Catalyst by 139.0% during the fourth quarter. HighMark Wealth Management LLC now owns 741,482 shares of the company’s stock worth $1,772,000 after buying an additional 431,200 shares during the period. Finally, Nepsis Inc. grew its stake in shares of Health Catalyst by 26.6% in the fourth quarter. Nepsis Inc. now owns 1,915,794 shares of the company’s stock valued at $4,579,000 after buying an additional 402,762 shares in the last quarter. 85.00% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Health Catalyst

Here are the key news stories impacting Health Catalyst this week:

• Positive Sentiment: Revenue and some profitability metrics showed resilience: Q4 revenue slightly beat consensus ($74.68M vs. $73.99M) and the company reported full‑year revenue of $311.1M with Adjusted EBITDA of $41.4M — signals that core demand remains. Health Catalyst Reports Fourth Quarter and Year End 2025 Results
• Positive Sentiment: Some chart/analyst commentary suggests the stock may be finding technical support (hammer pattern) and that earnings‑estimate revisions could stabilize — a possible near‑term bottom for opportunistic buyers. HCAT May Find a Bottom Soon
• Neutral Sentiment: Management has launched a strategic review and the CEO would not rule out a potential sale — this could unlock value but also creates uncertainty around capital allocation and timing. Seeking Alpha: CEO declines to rule out sale
• Negative Sentiment: The quarter showed an EPS miss and continued negative margins — Q4 EPS missed estimates (reported ~$0.08 vs. consensus around $0.10), which undercut confidence in near‑term profitability. MarketBeat Q4 results summary
• Negative Sentiment: Q1 revenue guidance was lowered to $68.0M–$70.0M vs. consensus ~ $74.1M — the guidance shortfall appears to be the main driver of the selloff since it signals softer near‑term top‑line momentum. Earnings press release / guidance
• Negative Sentiment: Multiple sell‑side firms lowered price targets and moved to neutral/hold/equal‑weight (Citigroup to $1.75, Stephens and Stifel to $2.00), increasing downward pressure and reducing buy‑side conviction. Analyst price-target cuts (Benzinga)
• Negative Sentiment: Market reaction was amplified by heavy volume and headlines emphasizing the mixed print and management uncertainty, leading to sharp intraday selling despite the revenue beat. MSN: stock reaction

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.